Bank of Montreal’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $125K | Buy |
40,693
+8,253
| +25% | +$35.7K | ﹤0.01% | 3076 |
|
|
2025
Q4 | $115K | Buy |
32,440
+9,485
| +41% | +$58.1K | ﹤0.01% | 3007 |
|
|
2025
Q3 | $204K | Buy |
22,955
+3,000
| +15% | +$30.4K | ﹤0.01% | 2767 |
|
|
2025
Q2 | $184K | Buy |
19,955
+76
| +0.4% | +$649 | ﹤0.01% | 2834 |
|
|
2025
Q1 | $171K | Hold |
19,879
| – | – | ﹤0.01% | 2777 |
|
|
2024
Q4 | $214K | Sell |
19,879
-1
| -0% | -$8 | ﹤0.01% | 2732 |
|
|
2024
Q3 | $113K | Buy |
19,880
+4,417
| +29% | +$25.5K | ﹤0.01% | 3208 |
|
|
2024
Q2 | $66.5K | Buy |
15,463
+1,437
| +10% | +$5.81K | ﹤0.01% | 3365 |
|
|
2024
Q1 | $71.7K | Buy |
14,026
+26
| +0.2% | +$146 | ﹤0.01% | 3371 |
|
|
2023
Q4 | $141K | Hold |
14,000
| – | – | ﹤0.01% | 3280 |
|
|
2023
Q3 | $108K | Buy |
+14,000
| New | +$111K | ﹤0.01% | 3259 |
|
|
2023
Q2 | – | Sell |
-12,295
| Closed | -$106K | – | 3970 |
|
|
2023
Q1 | $106K | Buy |
+12,295
| New | +$123K | ﹤0.01% | 3222 |
|
|
2022
Q1 | – | Sell |
-13,040
| Closed | -$235K | – | 4145 |
|
|
2021
Q4 | $235K | Buy |
+13,040
| New | +$248K | ﹤0.01% | 2891 |
|
|
2021
Q2 | – | Sell |
-23,692
| Closed | -$358K | – | 3741 |
|
|
2021
Q1 | $358K | Buy |
23,692
+13,575
| +134% | +$148K | ﹤0.01% | 2847 |
|
|
2020
Q4 | $56K | Buy |
10,117
+5,682
| +128% | +$29.9K | ﹤0.01% | 3888 |
|
|
2020
Q3 | $20K | Sell |
4,435
-1,643
| -27% | -$7.07K | ﹤0.01% | 3833 |
|
|
2020
Q2 | $29K | Buy |
6,078
+4,078
| +204% | +$15.4K | ﹤0.01% | 3680 |
|
|
2020
Q1 | $5K | Sell |
2,000
-5,468
| -73% | -$19.1K | ﹤0.01% | 3664 |
|
|
2019
Q4 | $19K | Buy |
7,468
+1,703
| +30% | +$4.47K | ﹤0.01% | 4332 |
|
|
2019
Q3 | $18K | Buy |
5,765
+182
| +3% | +$525 | ﹤0.01% | 4142 |
|
|
2019
Q2 | $19K | Sell |
5,583
-20,517
| -79% | -$63.7K | ﹤0.01% | 4198 |
|
|
2019
Q1 | $80K | Sell |
26,100
-3,933
| -13% | -$9.39K | ﹤0.01% | 3151 |
|
|
2018
Q4 | $47K | Buy |
30,033
+24,100
| +406% | +$54.7K | ﹤0.01% | 3295 |
|
|
2018
Q3 | $16K | Hold |
5,933
| – | – | ﹤0.01% | 3770 |
|
|
2018
Q2 | $15K | Buy |
5,933
+3,933
| +197% | +$11K | ﹤0.01% | 3833 |
|
|
2018
Q1 | $6K | Hold |
2,000
| – | – | ﹤0.01% | 3879 |
|
|
2017
Q4 | $6K | Hold |
2,000
| – | – | ﹤0.01% | 3895 |
|
|
2017
Q3 | $8K | Sell |
2,000
-75,000
| -97% | -$333K | ﹤0.01% | 3756 |
|
|
2017
Q2 | $410K | Hold |
77,000
| – | – | ﹤0.01% | 2355 |
|
|
2017
Q1 | $442K | Buy |
77,000
+75,000
| +3,750% | +$387K | ﹤0.01% | 2141 |
|
|
2016
Q4 | $8K | Sell |
2,000
-36,100
| -95% | -$129K | ﹤0.01% | 3647 |
|
|
2016
Q3 | $138K | Buy |
38,100
+36,100
| +1,805% | +$152K | ﹤0.01% | 2610 |
|
|
2016
Q2 | $12K | Hold |
2,000
| – | – | ﹤0.01% | 3539 |
|
|
2016
Q1 | $10K | Hold |
2,000
| – | – | ﹤0.01% | 3620 |
|
|
2015
Q4 | $11K | Buy |
+2,000
| New | +$14.2K | ﹤0.01% | 3586 |
|
Other funds holding AVXL
VCM
SF
VPM
Bank of Montreal's AVXL Position: Q1 2026 in Review
Bank of Montreal increased its Anavex Life Sciences (AVXL) stake by 25% in Q1 2026, buying an estimated $35.7K and bringing the position to 40,693 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #3076.
Bank of Montreal first reported a position in AVXL in Q4 2015 and has held it in 35 quarters since. The position peaked at $442K in Q1 2017. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.
- Bank of Montreal held 40,693 shares of Anavex Life Sciences worth $125K as of Q1 2026.
- Bank of Montreal bought 8,253 Anavex Life Sciences shares in Q1 2026, an estimated $35.7K.
- Anavex Life Sciences made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #3076 holding.
- Bank of Montreal first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 35 quarters since.
- Bank of Montreal's Anavex Life Sciences position peaked at $442K in Q1 2017.
- 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.
Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.